JPRN-UMIN000011820招募中未知
Efficacy of tight control of Infliximab (IFX) for Crohn's disease (CD) by CRP value and fecal concentration of calprotectin (Quattro C study) - Investigation of efficacy of tight control or withdrawal of Infliximab (IFX) for Crohn's disease (CD) by CRP value and fecal concentration of calprotectin
ationalOrganizationHospital Fukuyama medical center0 个研究点目标入组 15 人开始时间: 2013年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
under analysis
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients receiving IFX with 10 mg/kg dose Patients receiving IFX at interval of less than 6 weeks
研究者
相似试验
已完成
4 期
Study Investigating Tailored Treatment With Infliximab for Active Crohn's DiseaseCrohn's DiseaseNCT01442025Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives121
已完成
4 期
Precision dosing of infliximab (IFX): the efficacy and economic effect of *precision dosing* of maintenance treatment with IFX in comparison with standard IFX maintenance treatment in inflammatory bowel disease.Inflammatory Bowel disease10017969IBDNL-OMON42154Academisch Medisch Centrum80
已完成
不适用
Study of the pharmacokinetics of Infliximab (IFX) in moderate to severe Ulcerative ColitisInflammatory Bowel Disease10017969Ulcerative ColitisNL-OMON37516Academisch Medisch Centrum20
终止
3 期
Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)Rheumatoid ArthritisNCT00394589Merck Sharp & Dohme LLC43
Unknown
不适用
Comparison of the Performance of SB2-Infliximab With Originator Infliximab in the Measure of Serum Concentrations in SerumInflammatory Bowel DiseasesNCT03308357The Alfred6